कृपया अन्य खोज का प्रयास करें
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Edward Gibson | 50 | 2021 | Independent Non-Executive Director |
Elaine Sullivan | 62 | - | Member of Scientific Advisory Board |
Daniel F. Hoft | - | 2021 | Member of Scientific Advisory Board |
Luke O’Neill | 59 | 2021 | Independent Non-Executive Director & Member of Scientific Advisory Board |
Brendan Mary Buckley | 73 | 2022 | Member of Scientific Advisory Board & Independent Non Executive Director |
Ian O'Connell | 37 | 2021 | CFO & Director |
Jeremy Skillington | 53 | 2021 | CEO & Director |
Cathal Martin Friel | 59 | 2021 | Executive Chairman of The Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है